We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Getein Introduces New MAGICL 6000 Chemiluminescence Immunoassay Analyzer at MEDICA 2022

By LabMedica International staff writers
Posted on 13 Nov 2022
Print article
Image: The new MAGICL 6000 chemiluminescence immunoassay analyzer introduced at MEDICA 2022 (Photo courtesy of Getein)
Image: The new MAGICL 6000 chemiluminescence immunoassay analyzer introduced at MEDICA 2022 (Photo courtesy of Getein)

Getein Biotech, Inc. (Nanjing, China) is introducing new POC solutions, including analyzers and rapid tests, at the 2022 edition of MEDICA, the world's largest trade fair for medical technology, being held from 14 to 17 November in Düsseldorf, Germany.

At MEDICA 2022, Getein is introducing MAGICL 6000, a compact and innovative chemiluminescence immunoassay analyzer, with optimal choice for mid to high-workflow laboratories that require a one-step chemiluminescence solution. Highly productive and compact, the instrument enables fully automated operation and provides the fastest testing speed of any device of its size. Getein is also showcasing Metis 600, a bench-top two in one immuno-hemanalysis and hematology modular system.

Among its range of POC platforms being highlighted at the event is the Getein 1600 fully-automated immunofluorescence quantitative analyzer which combined with bar-coded, ready-to-use strip cassettes, delivers accurate testing results in minutes. In conjunction with dedicated immunofluorescence test kits, the Getein 1600 automates the detection and quantification of markers for cardiovascular disease, renal diseases, inflammation, fertility, diabetes mellitus, bone metabolism, tumor and thyroid in a biological sample. Visitors to the company’s booth at MEDICA 2022 can also experience the Getein 1180 immunofluorescence quantitative analyzer that is used to measure the concentration of biomarkers in human whole blood, serum, plasma, urine, nasal swab, or saliva samples. The results can be used as an aid in clinical diagnosis of laboratory and POC testing and is applicable in emergency departments, clinical labs, outpatient departments, ICU, CCU, cardiology, ambulance, inpatient wards, etc.

Also on display at MEDICA 2022 are the Getein 1160 multi-channel POCT analyzer which has four incubation channels and one emergency test channel, along with a constant test environment with 32℃ to ensure more accurate test results. The Getein 1160 is applicable in emergency departments, clinical labs, outpatient departments, ICU, CCU, cardiology, ambulance, inpatient wards, etc. Alongside the Getein 1160, the company is demonstrating the Getein 208 hand-held integrated system that works with dedicated test kits made by Getein. Getein 208 is intended to detect and quantify specific chemical components in human blood serum, plasma, whole blood, capillary blood and urine samples through dry chemistry and fluorescence immunoassay. Getein is also showcasing rapid tests at MEDICA 2022, including its Monkeypox Virus Real-time PCR Kit which is used for the qualitative detection of MPV in serum or lesion exudate samples.

Related Links:
Getein Biotech, Inc. 

Gold Member
Blood Gas Analyzer
GEM Premier 7000 with iQM3
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test
New
MTHFR Mutation Test
REALQUALITY THROMBO MTHFR
New
Automated Immunoassay Analyzer
Phadia 1000

Print article

Channels

Molecular Diagnostics

view channel
Image: The test could be a game changer for people with some of the most aggressive forms of cancer (Photo courtesy of UNE)

Blood Test Could Help More Women Survive Aggressive Triple Negative Breast Cancer

Cancer research shows that over 90% of women diagnosed with breast cancer at its earliest stage survive for five years or more. However, this survival rate dramatically decreases to just 30% when the cancer... Read more

Pathology

view channel
Image: The Results Manager System (Photo courtesy of QuidelOrtho)

Informatics Solution Elevates Laboratory Efficiency and Patient Care

QuidelOrtho Corporation (San Diego, CA, USA) has introduced the QuidelOrtho Results Manager System, a cutting-edge informatics solution designed to meet the increasing demands of modern laboratories.... Read more
Sekisui Diagnostics UK Ltd.